The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered.
Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.
Diagnosis of any subtype of medulloblastoma between the ages of 3 to 22 years or between the ages of 22 to 44 years with the sonic hedgehog (SHH) subtype of medulloblastoma
Radiotherapy on or according to the SJMB12 protocol
5 or more years since the initiation of radiation therapy and who did not have evidence of disease progression
Provision of informed consent by participant/guardian or legal representative; Assent by minor participant
Participants or their legal guardian/representative are unwilling or unable to provide written informed consent.
Participants who had relapsed or refractory disease during or following completion of treatment for medulloblastoma